Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

However, healthcare is a necessity. And the healthcare sector is poised to grow over the next decade and beyond with aging populations around the world. These factors make healthcare stocks a great ...

Pharmaceutical stocks can bring an element of safety to your portfolio. All of this equals a rather steady stream of revenue ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic ...

Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...

AbbVie will clearly fight to keep its top-selling Humira (adalimumab) anti-inflammatory drug on the market for as long as possible – but it also has one eye on a possible successor that is ...

TOKYO : Shares in Nippon Steel fell more than 1 per cent on Monday after U.S. President Joe Biden blocked its proposed $14.9 billion acquisition of U.S. Steel, dampening growth prospects for Japan ...

Its former lead drug is an anti-inflammatory injection called Humira. At recent prices, AbbVie stock offers a 3.7% yield. The company has more than quadrupled its dividend payout since spinning ...